Iron, brain ageing and neurodegenerative disorders
- PMID: 15496864
- DOI: 10.1038/nrn1537
Iron, brain ageing and neurodegenerative disorders
Abstract
There is increasing evidence that iron is involved in the mechanisms that underlie many neurodegenerative diseases. Conditions such as neuroferritinopathy and Friedreich ataxia are associated with mutations in genes that encode proteins that are involved in iron metabolism, and as the brain ages, iron accumulates in regions that are affected by Alzheimer's disease and Parkinson's disease. High concentrations of reactive iron can increase oxidative-stress induced neuronal vulnerability, and iron accumulation might increase the toxicity of environmental or endogenous toxins. By studying the accumulation and cellular distribution of iron during ageing, we should be able to increase our understanding of these neurodegenerative disorders and develop new therapeutic strategies.
Similar articles
-
Oxidative stress, mitochondrial dysfunction and cellular stress response in Friedreich's ataxia.J Neurol Sci. 2005 Jun 15;233(1-2):145-62. doi: 10.1016/j.jns.2005.03.012. J Neurol Sci. 2005. PMID: 15896810 Review.
-
Iron in neuronal function and dysfunction.Biofactors. 2010 Mar-Apr;36(2):103-10. doi: 10.1002/biof.80. Biofactors. 2010. PMID: 20232345 Review.
-
Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases.Mech Ageing Dev. 2005 Feb;126(2):317-26. doi: 10.1016/j.mad.2004.08.023. Mech Ageing Dev. 2005. PMID: 15621213 Review.
-
Role of iron in neurodegenerative disorders.Top Magn Reson Imaging. 2006 Feb;17(1):5-17. doi: 10.1097/01.rmr.0000245461.90406.ad. Top Magn Reson Imaging. 2006. PMID: 17179893 Review.
-
Age related mitochondrial degenerative disorders in humans.Biotechnol J. 2008 Jun;3(6):750-6. doi: 10.1002/biot.200800066. Biotechnol J. 2008. PMID: 18512864 Review.
Cited by
-
Effect of age on MRI phase behavior in the subcortical deep gray matter of healthy individuals.AJNR Am J Neuroradiol. 2013 Nov-Dec;34(11):2144-51. doi: 10.3174/ajnr.A3569. Epub 2013 May 30. AJNR Am J Neuroradiol. 2013. PMID: 23721902 Free PMC article.
-
Design and synthesis of N-hydroxyalkyl substituted deferiprone: a kind of iron chelating agents for Parkinson's disease chelation therapy strategy.J Biol Inorg Chem. 2021 Jun;26(4):467-478. doi: 10.1007/s00775-021-01863-x. Epub 2021 May 8. J Biol Inorg Chem. 2021. PMID: 33963933
-
Assessment of Protective Role of Multifunctional Dopamine Agonist D-512 Against Oxidative Stress Produced by Depletion of Glutathione in PC12 Cells: Implication in Neuroprotective Therapy for Parkinson's Disease.Neurotox Res. 2015 Nov;28(4):302-18. doi: 10.1007/s12640-015-9548-6. Epub 2015 Jul 23. Neurotox Res. 2015. PMID: 26201265 Free PMC article.
-
Striatal iron content predicts its shrinkage and changes in verbal working memory after two years in healthy adults.J Neurosci. 2015 Apr 29;35(17):6731-43. doi: 10.1523/JNEUROSCI.4717-14.2015. J Neurosci. 2015. PMID: 25926451 Free PMC article.
-
Molecular mechanisms of non-transferrin-bound and transferring-bound iron uptake in primary hippocampal neurons.J Neurochem. 2015 Jun;133(5):668-83. doi: 10.1111/jnc.13040. Epub 2015 Mar 10. J Neurochem. 2015. PMID: 25649872 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
